3-甲基-7-氧-9-氟-10-烃氧基(或芳氧基)-2,3-二氢-7H-吡啶[ 1,2,3-de]苯并恶嗪-6-羧酸及其类似物(英) 的合成和抗菌以及抗肿瘤活性

合成了3－甲基－7－氧－9－氟－10－烃氧基（或芳氧基）－2,3－二氢－7H－吡啶［1,2,3－de］苯并恶嗪－6－羧酸及其类似物,体外抗菌筛选证明10－烃氧基化合物（尤其是氟乙氧基化合物3d）的抗菌作用明显优于10－羟基化合物3a。体外抗肿瘤试验证明有的化合物对LAX和P388细胞株培养具有中等或较低的细胞毒。     

7-(吡啶-N-氧-2-巯基)-1-(2-氟乙基)-6,8-二氟-1,4-二氢-4-氧喹啉-3-羧酸的合成及抗菌活性

目的：根据喹诺酮类抗菌药和抗菌防腐剂２ － 巯基吡啶－ Ｎ－ 氧化物的抗菌作用原理设计、合成化合物７ － （ 吡啶－ Ｎ－ 氧－ ２ － 巯基） － １ － （２ － 氟乙基） － ６ ,８ － 二氟－ １ ,４ － 二氢－ ４ － 氧喹啉－ ３ － 羧酸,对其抗菌活性进行了研究。方法：合成此化合物,并研究其体外抗菌活性。结果：该化合物的体外抗菌活性优于国外近期上市的喹诺酮类抗菌药———氟罗沙星。结论：此类化合物有进一步研究的价值,为进一步研究喹诺酮类抗菌药提供了一个方向。     

1-烷基-6-氟-1,4-二氢-7-(4-酰基-1-哌嗪基)-4-氧代喹啉-3-羧酸类似物的合成及其抗菌活性

目的 设计合成具有广谱抗菌活性的含氟喹诺酮类化合物。方法 利用吡酮酸7位哌嗪基4位氮上存在的活性氢为反应修饰基点，与磺酰氯，酰氯，氯甲酸酯进行Schotten-Baumann酰基化反应设计合成一系列含有磺酰基、酰基和烷氧羰基类氟喹诺酮类似物。结果 合成了20个含有磺酰基、酰基和氧羰基的氟喹诺酮类似物，利用元素分析、核磁共振进行了结构确认。结论 合成了16个未见报道的新化合物，初步体外活性测试结果表明，其中的4个化合物有较高的生物活性。     

7-取代-1-乙基(2-氟乙基)-6,8-二氟-1,4-二氢-4-氧喹啉-3-羧酸的合成及抗菌活性

７取代１乙基（２氟乙基）６，８二氟１，４二氢４氧喹啉３羧酸的合成及抗菌活性鄢立刚徐炳祥马振瀛朱艳静杨倩华（沈阳市沈阳军区后勤部军事医学研究所，沈阳１１００３１；上海市第二军医大学药学院中西药研究室，上海２００４...     

7-取代-1-乙基(2-氟乙基)-6,8-二氟-1,4-二氢-4-氧喹啉-3-羧酸的合成及抗菌活性

Eighteen 7-substituted-1-ethyl (2-fluoroethyl)-6, 8-difluoro-1, 4-dihydro-4-oxoquinolone-3-carboxylic acid were designed and synthesized. The results of preliminary antibacterial test showed that most of the compounds exhibited definite activities in test against pathogenic bacteria. Especially, compound 17 and 18 showed better activities and surpassed fleroxacin when compared in vitro.     

吡酮酸类抗茵药物的研究XVI．6-氟-1-（2-氟-5-吡啶基）-7-（1一哌嗪基）-1，4-二氢-4-氧代喹啉-3-羧酸及其类似物的合成与抗茵作用

合成了14个6-氟-1-(2-氟-5-吡啶基)-5．7．8-不同取代-1．4-二氢-4-氧代喹啉-3-羧酸及其类似物．测定了它们对14株革兰氏阳性和革兰氏阴性细菌的MIC值．并与环丙沙星对照。结果表明,这些化合物的抗菌活性均很弱。     

7—（3—羟基—1，5—二氮杂环庚烷—1—胺基）—1—环丙基—6—氟—1，4—二氢—4氧代喹啉—3—羧酸及其类似物的合成与抗菌活性

设计并合成了新化合物7－（3－羟基－1,5－二氮杂环庚烷－1－胺基）－1－环丙基－6－氟－1,4－二氢－4氧代喹啉－3－羧酸（5a)及其类似物5b-5d,采用标准二倍稀释法测定了其对26株有代表性的革兰氏阳性及革兰氏阴性菌的体外抗菌活性。结果表明化合物5a-5d对所测菌株的抑菌活性低于司帕沙星,而5a和5e则对革兰氏阳性菌金葡球菌有较高的活性,其最低抑菌浓度MIC值为0．125mg/L。     

5-氨基-6,8-二氟-1-(5-氟-2-吡啶基)-7-(3-甲基-1-哌嗪基)-1,4-二氢-4-氧代喹啉-3-羧酸及其类似物的合成及其抗菌作用

目的设计合成1-位为5-氟-2-吡啶基的吡酮酸衍生物,并对其抗菌活性进行初步评价.方法以2,3,4,5-四氟-6-硝基苯甲酰基乙酸乙酯和2,4,5-三氟-3-甲氧基苯甲酰基乙酸乙酯为原料,经多步反应合成8个5-氨基-6,8-二氟-1-(5-氟-2-吡啶基)-7-(3-甲基-1-哌嗪基)-1,4-二氢-4-氧代喹啉-3-羧酸及其类似物.结果共合成15个新化合物,经¹HNMR和MS确证其结构,其中8个(8-15)为目标物.结论8个目标物对金黄色葡萄球菌-16、大肠埃希氏菌-26和铜绿假单孢菌-17的体外活性均低于环丙沙星.     

7-(7-氨甲基-5-氮杂螺［2,4］庚烷-5-基)-1-环丙基-6-氟-8-甲氧基-1,4-二氢-4-氧代喹啉-3-羧酸及其类似物的合成与抗菌作用7-(7-氨甲基-5-氮杂螺［2,4］庚烷-5-基)-1-环丙基-6-氟-8-甲氧基-1,4-二氢-4-氧代喹啉-3-羧酸及其类似物的合成与抗菌作用

目的寻找新的广谱、高效、低毒喹诺酮类抗菌药物。方法设计合成7-(7-氨甲基-5-氮杂螺［2,4］庚烷-5-基)-1-环丙基-6-氟-8-甲氧基-1,4-二氢-4-氧代喹啉-3-羧酸及其类似物,测定其体内外活性。结果共合成了20个新化合物,经¹HNMR,MS和HRMS确证其结构。其中5个目标化合物(22～26)有广谱活性,尤其对革兰氏阳性菌具有很强的活性。其中化合物24对所试的13株革兰氏阳性菌的MIC值均0.03 mg·L^-1,其活性优于对照药克林沙星和加替沙星,对所试的6株革兰氏阴性菌,其活性相当于或低于对照药。结论化合物(22～26)值得进一步评价。     

7-(吡啶-N-氧-2-巯基)-1-(2-氟乙基)-6,8-二氟-1,4-二氢-4-氧喹啉-3-羧酸的合成及抗菌活性

目的;根据喹诺酮类抗菌药和抗菌防腐剂２－巯基吡啶－Ｎ－氧化物的抗菌作用原理设计,合成化合物７－（吡啶－Ｎ－氧－２－巯基）－１－（２－氟乙基）－６,８－二氟－１,４－二氢－４－氧喹啉－３－羧酸,对其抗菌活性进行了研究。方法;合成此化合物,并研究其体外抗菌活性。     

(S)-(-)-9-氟-2,3-二氢-3-甲基-10-[4-(2-吡啶)-1-基哌嗪]-7-氧代-7H-吡啶[1,2,3-de][1,4]苯并噁嗪-6-羧酸(YH-6)与其它抗微生物药体外抗支原体活性的比较(英文)

目的:测定新喹诺酮YH-6对支原体的抑制活性并与其它抗微生物药剂作比较。方法:MIC的测定采用微量稀释法。结果:YH-6对解脲支原体(Uu),人型支原体(Mh),口腔支原体(Mo),唾液支原体(Ms)的MIC分别为250μg·L~(-1),500μg·L~(-1),125μg·L~(-1),125μg·L~(-1),它的抑制活性与红霉素,柱晶白霉素相当,是氧氟沙星的2-8倍。Uu,Mh对YH-6及交沙霉素和泰洛星不易产生诱导耐药性,而对红霉素和四环素易产生诱导耐药性和多重耐药性,而对YH-6,交沙霉素和泰洛星无多重耐药性。结论:YH-6对支原体有很强的抑制活性,且不易形成诱导耐药性。Uu和Mh的红霉素或四环素抗性菌株对YH-6无多重耐药性。     

Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin)

A short and efficient synthesis, starting with (R)- and (S)-alaninol, of the two optical antipodes of the quinolone antimicrobial agent ofloxacin has been devised. Testing in vitro of the products against a range of bacteria and in an assay system incorporating purified DNA gyrase from different bacterial species demonstrates that the S-(-) enantiomer is substantially the more active.     

Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids

A series of pyridobenzothiazine acid derivatives was synthesized and their in vitro antibacterial activity was evaluated. The 1,4-benzothiazine intermediates, which by Gould-Jacobs quinoline synthesis produced pyridobenzothiazine acids, were prepared by hydrolytic basic cleavage of substituted 2-aminobenzothiazoles and successive cyclocondensation with 1-bromo-2-chloroethane or alternatively with monochloroacetic acid, hence reduction by LiAlH4. The pyridobenzothiazine acids 10c, 30, and 31 show potent antibacterial activities against Gram-positive and Gram-negative pathogens. Structure-activity relationships are discussed. The compound 9-fluoro-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-d e] [1,4]benzothiazine-6-carboxylic acid (31) (MF-934) has been found to possess, together with the antibacterial activity, a weak acute toxicity and interesting pharmacokinetic characteristics in several animal species (rat, dog, monkey, man).     

Four-week sub-acute toxicity study of S-(-)-9-fluoro-2,3-dihydro-3-methyl-10- (4-methyl-1-piperazinyl)-7-oxo-7H-pyrido-[1,2,3,-de] [1,4]benzoxazine-6- carboxylic acid hemihydrate (DR-3355) in CD rats and cynomolgus monkeys

S-(-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H -pyrido-[1,2,3,-de] [1,4]benzoxazine-6-carboxylic acid hemihydrate, DR-3355, a new quinolone antimicrobial agent, was administered by oral gavage to groups of ten male and ten female CD rats at dosages of 50, 200 or 800 mg/kg/day and to groups of three male and three female cynomolgus monkeys at dosages of 10, 30, or 100 mg/kg/day. Both species were treated for four weeks. The vehicle (0.5% sodium carboxymethyl cellulose)-treated group served as control. Rats at the high dose showed salivation, slight increases in total leucocyte and lymphocyte counts, slight changes in the plasma electrolyte balance, and minor reductions in urea concentration. The articular surfaces of the humerus and femur of rats at the high dose showed minor degenerative changes. Increased caecal weight occurred in rats at all the treatment groups. Monkeys at the high dose showed salivation, diarrhoea and lost weight. There was no microscopic change in the tissues examined. No effect levels under these conditions were established at 200 mg/kg/day in the rat, and 30 mg/kg/day in the monkey.     

（S）—（—）—9—氟—2,3—二氢—3—甲基—10—[4—（2—吡啶）—1—基哌嗪]—7—？…

AIM: To determine the susceptibilities of Mycoplasma and Ureaplasma to (S)-(-)-9-fluoro-2,3-dihydro-3-methyl-10 -[4-(2-pyridyl)-1-piperazinyl]-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine -6-carboxylic acid (YH-6) and to compare it with those referential quinolones, macrolides, and tetracyclines. METHODS: The minimum inhibitory concentration (MIC) were determined by microdilution method in vitro. RESULTS: The MIC of YH-6 for Ureaplasma urealyticum (Uu: 250 micrograms.L-1), Mycoplasma hominis (Mh: 500 micrograms.L-1), M orale (Mo: 125 micrograms.L-1) and M salivarium (Ms: 125 micrograms.L-1) were closely similar to those of macrolides (erythromycin and leucomycin) and were 2-8 folds greater than those of ofloxacin (Ofl). Uu and Mh easily induced resistance to erythromycin and tetracycline. They did not easily form resistance to quinolone (YH-6, Ofl), josamycin and tylosin. Tetracycline-resistance (Tcr) or erythromycin-resistance (EMr) strains of Uu (or Mh) had cross-resistance to erythromycin or tetracycline. However, they had no cross-resistance to quinolone, josamycin and tylosin. CONCLUSION: YH-6 was a highly active quinolone against Mycoplasma, but could hardly induce resistance to Uu. EMr- or Tcr- strains of Uu (or Mh) had no cross-resistance to YH-6.     

Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent

Novel pyrido[1,2,3- de][1,4]benzoxazine-6-carboxylic acid derivatives 5- 9 carrying a 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl moiety at the C-10 position were synthesized and their in vitro antibacterial activity, intravenous single-dose toxicity, convulsion inductive ability, and phototoxicity were evaluated. It appeared evident that compounds 5a, 6a, 8a, and 9a, which have a cis-oriented 4-methyl or 4-fluoro-3-cyclopropylaminomethyl-1-pyrrolidinyl moiety at the C-10 position, exhibited 2- to 16-fold more potent in vitro antibacterial activity than clinafloxacin against quinolone-resistant Gram-positive clinical isolates. Furthermore, it was obvious that introduction of a fluorine atom to the C-4 position of the 3-cyclopropylaminomethyl-1-pyrrolidinyl moiety reduced intraveneous single-dose acute toxicity and the convulsion inductive ability, and introduction of a fluorine atom to the C-3 methyl group of the pyridobenzoxazine nucleus eliminated the phototoxicity.     

吡酮酸类抗菌药物的研究Ⅷ.1-对氟苯基-6-氟-1,4-二氢-4-氧-7-(1-哌嗪)噌啉-3-羧酸及其类似物的合成和构效关系

为探讨构效关系,合成了1-对氟苯基-6-氟-1,4-二氢-4-氧-7-(1-哌嗪)噌啉-3-羧酸及其喹啉、萘啶、吡啶[2,3-C]哒嗪环系类似物16个。测定了对大肠杆菌的MIC。用Hückel分子轨道理论(HMO)方法计算了四个母体环上电子密度。结果表明:环中氮的位置对药效团——3位羧基和4位羰基氧原子上电子密度的影响较大而影响其抗菌活性。喹啉、萘啶两环系的3位羧基和4位羰基氧原子上的电子密度较高,其体外抗菌活性较高;而噌啉及吡啶[2,3-C]哒嗪两环系的电子密度较低,其体外抗菌活性较低甚至消失。     

Synthesis and in-vitro antibacterial activity of 7-(3-aminopyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives

A series of novel 7-(3-aminopyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives was designed, synthesized and characterized by (1)H-NMR, MS and HRMS. These fluoroquinolones were evaluated for their in-vitro antibacterial activity against representative Gram-positive and Gram-negative strains. Generally, all of the target compounds display rather weak potency against the tested Gram-negative strains, but most of them exhibit good potency in inhibiting the growth of S. aureus including methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis including methicillin-resistant S. epidermidis (MRSE) (MIC: 0.125-8 μg/mL). In particular, the compound 9g is 2 to 32 fold more potent than gemifloxacin (GM), moxifloxacin (MX), gatifloxacin (GT), and levofloxacin (LV) against S. pneumoniae 08-3, K. pneumoniae 09-23, and P. aeruginosa ATCC27853, 4 to 32 fold more potent than MX, GM, and LV against K. pneumoniae 09-21, and more active than or comparable to the four reference drugs against P. aeruginosa 09-32.